The NIAAA requires continued whole-exome sequencing analysis of its Clinical Center patient cohort to identify genetic causes of alcohol-related disorders, using the same AmpliSeq Exome enrichment system and ION sequencing platform to maintain analytical integrity. This consistency is essential because over 2,000 patients have already been analyzed on this platform, and each sequencing platform has a unique error pattern. The work involves analyzing sequence variant differences and changes in treatment response over many years. No specific budget amount, performance location, or non-bid timelines are mentioned in the description.